Drug Profile
Research programme: dual cyclooxygenase/5-lipoxygenase inhibitors - Amira/Roche
Alternative Names: 1,5-diarylpyrazole-propanoic acid derivatives; 1,5-diarylpyrazole-propanoic acidsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche
- Developer Amira Pharmaceuticals; Roche
- Class Propionic acids; Pyrazoles
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Europe
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb